News

June 18, 2019

Colorectal Cancer Vaccine Candidate Induces Potent Immune Responses, Interim Trial Results Show

News

A single dose of PolyPEPI1018 — Treos Bio’s investigational off-the-shelf vaccine for colorectal cancer — induced promising immune responses and clinical signs of efficacy when given in combination with standard ... Read more

June 14, 2019

Tecentriq Combo Prolongs Life of Lung Cancer Patients with Liver Metastases, Phase 3 Study Shows

News

Adding Tecentriq (atezolizumab) to a combination of Avastin (bevacizumab) and chemotherapy cut the risk of death by nearly half in a group of metastatic non-small cell lung cancer (NSCLC) patients ... Read more

June 12, 2019

FDA Approves Keytruda for Metastatic or Recurrent Head and Neck Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line therapy for patients with metastatic or recurrent and inoperable head and neck squamous cell carcinoma (HNSCC) whose ... Read more

June 11, 2019

Keytruda Improves Survival of Patients with Recurrent or Metastatic Head, Neck Cancer, Phase 3 Trial Shows

News

First-line treatment with Keytruda (pembrolizumab) in combination with chemotherapy prolongs the survival of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), compared to standard of care treatment, ... Read more

June 7, 2019

Imfinzi Still Improving Survival Rates in Advanced NSCLC Patients, PACIFIC Update Shows

News

AstraZeneca‘s Imfinzi (durvalumab) continues to demonstrate superior overall survival compared to placebo when given to patients with stage III, inoperable non-small-cell lung cancer (NSCLC) whose disease did not progress after platinum-based chemotherapy and ... Read more

June 5, 2019

Kite’s Investigational CAR-T Cell Therapy Shows Promise in Phase 1/2 Trial

News

A single infusion of KTE-X19, Kite Pharma‘s investigational CD19 CAR-T cell therapy, leads to high response rates in patients with relapsed or refractory acute lymphoblastic leukemia (ALL), Phase 1/2 trial ... Read more

June 4, 2019

Phase 1/2 Trial of Immunotherapy AGI-134 to Open to US Patients with Solid Tumors

News

BioLineRx is expanding the Phase 1/2 clinical trial of its investigational AGI-134 to include the U.S., now that regulatory officials there have approved the company’s request to test the treatment. ... Read more

May 29, 2019May 29, 2019

Cue Biopharma to Launch CUE-101 Immunotherapy Trial for Head and Neck Cancer Caused by HPV

News

The U.S. Food and Drug Administration (FDA) has accepted Cue Biopharma‘s investigational new drug (IND) application for its immunotherapy candidate CUE-101, clearing the way for the first-in-human Phase 1 trial ... Read more

May 28, 2019May 28, 2019

Cosibelimab Shows Signs of Anti-cancer Activity Against Multiple Tumor Types in Phase 1 Trial

News

Treatment with Checkpoint Therapeutics’ investigational immunotherapy Cosibelimab supports a positive anti-cancer response in approximately 28% of patients with advanced solid tumors, interim results from an ongoing Phase 1 trial show. In ... Read more

May 24, 2019

Trial Testing EDV Nanocells in Pancreatic, Other EGFR-positive Advanced Solid Cancers Now Dosing Patients

News

A Phase 1/2 clinical trial has started dosing participants to test EnGeneIC‘s second-generation cytotoxic-loaded EDV nanocells as a treatment for EGFR-positive solid cancers who have exhausted all other therapeutic alternatives. The ... Read more